Provided by Tiger Trade Technology Pte. Ltd.

Compass Therapeutics, Inc.

6.17
-0.2200-3.44%
Post-market: 6.280.1100+1.78%19:46 EST
Volume:1.36M
Turnover:8.43M
Market Cap:1.10B
PE:-13.67
High:6.43
Open:6.31
Low:6.14
Close:6.39
52wk High:6.88
52wk Low:1.33
Shares:177.86M
Float Shares:123.05M
Volume Ratio:0.82
T/O Rate:1.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4512
EPS(LYR):-0.3594
ROE:-37.82%
ROA:-23.47%
PB:5.24
PE(LYR):-17.17

Loading ...

William Blair Initiates Compass Therapeutics at Outperform

MT Newswires Live
·
Jan 05

BRIEF-Compass Therapeutics Files For Up To $400 Million Mixed Shelf Offering- SEC Filing

Reuters
·
Dec 31, 2025

Compass Therapeutics Files $400 Million Mixed Shelf

MT Newswires Live
·
Dec 31, 2025

Compass Therapeutics Inc - Files for up to $400 Mln Mixed Shelf Offering- SEC Filing

THOMSON REUTERS
·
Dec 31, 2025

Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference

GlobeNewswire
·
Dec 17, 2025

Compass Therapeutics Initiated at Buy by Canaccord Genuity

Dow Jones
·
Dec 03, 2025

Cantor Fitzgerald Initiates Compass Therapeutics at Overweight

MT Newswires Live
·
Dec 03, 2025

Compass Therapeutics Inc. : Leerink Partners Raises Target Price to $11 From $7

THOMSON REUTERS
·
Nov 26, 2025

Compass Therapeutics (CMPX) Receives a Buy from Piper Sandler

TIPRANKS
·
Nov 10, 2025

Compass Therapeutics Inc. expected to post a loss of 11 cents a share - Earnings Preview

Reuters
·
Nov 07, 2025

Positive Outlook for Compass Therapeutics: Buy Rating Justified by Promising Developments and Strong Financial Position

TIPRANKS
·
Nov 06, 2025

Compass Therapeutics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Nov 05, 2025

Compass Therapeutics Q3 EPS $(0.08) Beats $(0.14) Estimate

Benzinga
·
Nov 05, 2025

Compass Therapeutics posts $14.3 million net loss for third quarter 2025

Reuters
·
Nov 05, 2025

Compass Therapeutics Inc. - Expects Phase 2/3 Companion-002 Study of Tovecimig Os and Pfs Data in Late Q1 2026

THOMSON REUTERS
·
Nov 05, 2025

Compass Therapeutics Q3 EPS USD -0.08

THOMSON REUTERS
·
Nov 05, 2025

Compass Therapeutics Q3 Net Income USD -14.259 Million

THOMSON REUTERS
·
Nov 05, 2025

Compass Therapeutics Inc. - Plans Ctx-10726 Ind Filing for Q4 2025 With Initial Phase 1 Clinical Data Expected in H2 2026

THOMSON REUTERS
·
Nov 05, 2025

Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire
·
Nov 05, 2025

Compass Therapeutics management to meet with Piper Sandler

TIPRANKS
·
Oct 22, 2025